Alto Neuroscience Files 8-K with Definitive Agreement Update

Ticker: ANRO · Form: 8-K · Filed: 2025-02-03T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-update, sec-filing

TL;DR

Alto Neuroscience just filed an 8-K – looks like a big new deal is in the works.

AI Summary

Alto Neuroscience, Inc. filed an 8-K on February 3, 2025, reporting an entry into a material definitive agreement and providing updates on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Mountain View, California.

Why It Matters

This 8-K filing signals a significant development for Alto Neuroscience, potentially involving a new material agreement that could impact its operations and financial future.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks, and the lack of specific details in this initial report warrants a medium risk assessment.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Alto Neuroscience?

The filing indicates an entry into a material definitive agreement, but the specific details of this agreement are not provided in the initial summary of the 8-K.

What information is provided regarding Alto Neuroscience's results of operations and financial condition?

The 8-K states that the company is reporting on its results of operations and financial condition, but specific financial figures or operational details are not elaborated upon in the provided text.

When was this 8-K report filed and what is the earliest event date reported?

The 8-K report was filed on February 3, 2025, and the earliest event reported is also February 3, 2025.

Where are Alto Neuroscience's principal executive offices located?

Alto Neuroscience's principal executive offices are located at 650 Castro Street, Suite 450, Mountain View, CA 94041.

What is Alto Neuroscience's standard industrial classification?

Alto Neuroscience's Standard Industrial Classification is Pharmaceutical Preparations [2834].

From the Filing

0001193125-25-019318.txt : 20250203 0001193125-25-019318.hdr.sgml : 20250203 20250203163905 ACCESSION NUMBER: 0001193125-25-019318 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250203 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250203 DATE AS OF CHANGE: 20250203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 25583152 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 8-K 1 d843857d8k.htm 8-K 8-K false 0001999480 0001999480 2025-02-03 2025-02-03     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025     ALTO NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter)       Delaware   001-41944   83-4210124 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   650 Castro Street , Suite 450 , Mountain View , CA   94041 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (650) 200-0412 N/A (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   ANRO   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 1.01 Entry into a Material Definitive Agreement On February 3, 2025, Alto Neuroscience, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), through or to the Agent (the “ATM Offering”). The ATM Shares will be offered and sold pursuant to a Registration Statement on Form S-

View on Read The Filing